<DOC>
	<DOCNO>NCT01498185</DOCNO>
	<brief_summary>To obtain safety tolerability information patient type 1 diabetes Dapagliflozin add Insulin ( 14 day )</brief_summary>
	<brief_title>BMS - Safety , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Dapagliflozin Type 1 Diabetes</brief_title>
	<detailed_description>Study Classification : Safety , Pharmacokinetics Pharmacodynamics</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetes central lab Glycosylated hemoglobin ( A1C ) ≥ 7.0 % ≤ 10.0 % Insulin use least 12 month initiation immediately diagnosis diabetes Method Insulin administration [ multiple daily injection ( MDI ) continuous subcutaneous Insulin infusion ( CSII ) ] stable ≥ 3 month Stable basal Insulin dose ≥ 2 week Ages 18 65 year Central laboratory Cpeptide value &lt; 0.7 ng/mL Body mass index ( BMI ) 18.5 35.0 kg/m2 History type 2 diabetes mellitus ( T2DM ) , maturity onset diabetes young ( MODY ) , pancreatic surgery chronic pancreatitis Oral hypoglycemic agent History diabetes ketoacidosis ( DKA ) within 24 week History hospital admission glycemic control within 6 month Frequent episodes hypoglycemia ( 2 unexplained within 3 month ) hypoglycemic unawareness Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) Serum total bilirubin &gt; 2X Upper limit normal ( ULN ) Abnormal Free T4 [ screen Thyroid Stimulating Hormone ( TSH ) abnormal ] Estimated glomerular filtration rate ( eGFR ) Modification Diet Renal Disease ( MDRD ) formula ≤ 60 mL/min/1.73m2 Cardiovascular ( CV ) /Vascular Diseases within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>